Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial Article

Industry Collaboration International Collaboration

cited authors

  • Yang, James Chih-Hsin; Han, Baohui; Jimenez, Emmanuel De La Mora; Lee, Jong-Seok; Koralewski, Piotr; Karadurmus, Nuri; Sugawara, Shunichi; Livi, Lorenzo; Basappa, Naveen S.; Quantin, Xavier; Dudnik, Julia; Ortiz, Diego Moran; Mekhail, Tarek; Okpara, Chinyere E.; Dutcus, Corina; Zimmer, Zachary; Samkari, Ayman; Bhagwati, Niyati; Csoszi, Tibor

authors

Publication Date

  • June 1, 2024

webpage

published in

category

keywords

  • Lenvatinib
  • Non-small cell lung cancer
  • Pembrolizumab
  • Programmed cell death-ligand 1

start page

  • 941

end page

  • 953

volume

  • 19

issue

  • 6